📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 21/02/2020
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPVVNaRlV6Q2RrSGJaVjRIdzJsRTRsOXBWZXQ4RzR3SDhUamVfRzNTWFVFMjkzWklaNTN6RVhVUWtsZ0Z5dVJvS1dUZERKeHJSMkVscHQ4V0ZlcHlRNlVCXzFnMkx3Ny1JZHlzcmtyTTlkdDVmZ1NFVzdwRGhPUXZZeHZsOXdKZ3FZRVoyOFdic01CYUJjbFd3Y3VXUnBXV1BuaVNqOGltX3NJOGhmVTZnczlXVTN1UUJOSm
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2001
PURPOSE: To compare a full-dose epirubicin-cyclophosphamide (HEC) regimen with classical cyclophosphamide, methotrexate, and fluorouracil (CMF) therapy and with a moderate-dose epirubicin-cyclophosphamide regimen (EC) in the adjuvant therapy of node-positive breast cancer. PATIENTS AND METHODS: Node-positive breast cancer patients who were aged 70 years or younger were randomly allocated to one of the following treatments: CMF for six cycles (oral cyclophosphamide); EC for eight cycles (epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2; day 1 every 3 weeks); and HEC for eight cycles (epirubicin 100 mg/m2, cyclophosphamide 830 mg/m2; day 1 every 3 weeks). RESULTS: Two hundred fifty-five, 267, and 255 eligible patients were treated with CMF, EC, and HEC, respectively. Patient characteristics were well balanced among the three arms. One and three cases of congestive heart failure were reported in the EC and HEC arms, respectively. Three cases of acute myeloid leukemia were reported in the HEC arm. After 4 years of median follow-up, no statistically significant differences were observed between HEC and CMF (event-free survival [EFS]: hazards ratio [HR] = 0.96, 95% confidence interval [CI], 0.70 to 1.31, P = .80; distant-EFS: HR = 0.97, 95% CI, 0.70 to 1.34, P = .87; overall survival [OS]: HR = 0.97, 95% CI, 0.65 to 1.44, P = .87). HEC is more effective than EC (EFS: HR = 0.73, 95% CI, 0.54 to 0.99, P = .04; distant-EFS: HR = 0.75, 95% CI, 0.55 to 1.02, P = .06; OS HR = 0.69, 95% CI, 0.47 to 1.00, P = .05). CONCLUSION: This three-arm study does not show an advantage in favor of an adequately dosed epirubicin-based regimen over classical CMF in the adjuvant therapy of node-positive pre- and postmenopausal women with breast cancer. Moreover, this study confirms that there is a dose-response curve for epirubicin in breast cancer adjuvant therapy.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2001 · Clinical Trial
Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, et al.